Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
IRWD
Strong BuyFLAGIronwood Pharmaceuticals, Inc. · Healthcare · United States · $682M · Avg Vol: $8M/d
Ironwood demonstrates strong product-market fit with high-growth assets like LINZESS and a robust pipeline. While the company's financial performance is strong, the recent insider selling (0.09%) creates a signal contradiction that warrants a cautious approach despite the otherwise solid fundamentals.
COMPANY DESCRIPTION
Ironwood Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal (GI) diseases. The company's flagship product, LINZESS/CONSTESS, is a market leader for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Ironwood's competitive edge is derived from its proven commercialization capabilities, a pipeline of novel GI candidates, and strategic collaborations that broaden its reach in this underserved therapeutic area.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 410.6M | 442.7M | 351.4M | 296.2M | -10.3% | 389.3M | 471.6M | 493.8M | 29.1% |
| EPS | 1.13 | -6.45 | 0.01 | 0.15 | -49.0% | 0.79 | 1.21 | 1.47 | 213.4% |
| Shares | 154.0M | 156.4M | 160.2M | 163.1M | +5.9% | 165.2M | — | — | — |
| Debt | 415.9M | 715.5M | 599.5M | 597.8M | 12.9% | 396.9M | — | — | — |
| Equity | 652.4M | -346.3M | -301.3M | -261.8M | — | — | — | — | — |
| Op CF | 273.8M | 183.4M | 103.5M | 127.0M | -22.6% | 185.6M | — | — | — |
| Inv CF | -0.1M | -1.0B | -0.1M | -34.0K | — | — | — | — | — |
| Fin CF | -237.6M | 277.2M | -107.0M | 0.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IRWD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IRWD | Ironwood Pharmaceuticals, Inc.(you) | $682M | 100 | Strong Buy |
| AMPH | Amphastar Pharmaceuticals, Inc. | $936M | 92 | Strong Buy |
| GTII.CN | Green Thumb Industries Inc. | $1.6B | 95 | Strong Buy |
| PCRX | Pacira BioSciences, Inc. | $1.0B | 86 | Strong Buy |
| ANIP | ANI Pharmaceuticals, Inc. | $1.7B | 92 | Strong Buy |
| COLL | Collegium Pharmaceutical, Inc. | $786M | 72 | Buy |
| TRLV | Trulieve Cannabis Corp. | $2.3B | 90 | Strong Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.5B | 89 | Strong Buy |
| INDV | Indivior Pharmaceuticals, Inc. | $4.1B | 94 | Strong Buy |
| EOLS | Evolus, Inc. | $587M | 60 | Hold |
Peer medians: ROE -25.8% · P/E 29.6x · Gross margin 58.7%